Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
CXCR4
MALT lymphoma
PET
PET/MRI
[68Ga]-Pentixafor
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
10
2018
accepted:
28
03
2019
entrez:
9
7
2019
pubmed:
10
7
2019
medline:
3
7
2020
Statut:
epublish
Résumé
MALT lymphomas express the chemokine receptor CXCR4 on a regular basis, and [68Ga]Ga-Pentixafor-PET has been shown to quantify CXCR4 expression non-invasively. We, therefore, aimed to evaluate [68Ga]Ga-Pentixafor-PET/MRI for the non-invasive assessment of MALT lymphomas. We included 36 MALT lymphoma patients, who had not undergone previous systemic or radiation therapy, in our prospective, IRB-approved, proof-of-concept study. Involved anatomic regions were the orbit (n=14), stomach (n=10), lungs (n=5), and other sites (soft-tissues n=3; adrenal gland, tonsils, parotid gland, and urinary bladder n=1, respectively). MRI sequences included an axial 2-point Dixon T1 VIBE SPAIR 3D sequence for PET attenuation correction; a coronal T2 HASTE sequence; and an axial echo-planar imaging SPAIR-based diffusion-weighted sequence (DWI) obtained during free-breathing (b-values, 50 and 800), with corresponding ADC (apparent diffusion coefficient) maps. In 33/36 patients, there were MALT lymphomas with an increased uptake of [68Ga]Ga-Pentixafor; all current lymphoma manifestations showed an increased uptake and, accordingly, were positive on the PET/MRI. The remaining three patients had undergone surgery for their orbital MALT lymphomas prior to PET/MRI. Mean SUVmax was 8.6 ± 4.7, mean SUVmean was 4.7 ± 1.8, and mean SUVpeak was 8.0 ± 4.2. The mean SUVmax of the liver was 1.8, and the mean tumor-to-liver ratio was 2.9 ± 2.0. There were no significant differences in SUVmax (P=0.22), SUVmean (P=0.53), SUVpeak (P=0.29), or SUVt/l (P=0.92) between the four anatomic regions (orbit, stomach, lungs, other). The mean tumor volume was 146 ± 499. Our results thus indicate that [68Ga]Ga-Pentixafor-PET is feasible for the assessment of MALT lymphomas, with a good tumor-to-background ratio in terms of radiotracer uptake.
Identifiants
pubmed: 31281504
doi: 10.7150/thno.31032
pii: thnov09p3653
pmc: PMC6587159
doi:
Substances chimiques
68Ga-pentixafor
0
CXCR4 protein, human
0
Coordination Complexes
0
Gallium Radioisotopes
0
Peptides, Cyclic
0
Receptors, CXCR4
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3653-3658Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Déclaration de conflit d'intérêts
Competing Interests: H.W. is a founder and shareholder of Scintomics. S.K. is CEO of Scintomics. M.Ma. received research grants and honoraria for presentations from Siemens Healthineers. A.R.H. received research grants from Siemens Healthineers. The other authors declare no competing financial interests.
Références
Leukemia. 2001 May;15(5):752-6
pubmed: 11368435
J Clin Oncol. 2006 Jul 1;24(19):3136-41
pubmed: 16769982
Gut. 2011 Jun;60(6):747-58
pubmed: 21317175
Blood. 2012 Apr 26;119(17):3917-24
pubmed: 22308295
Theranostics. 2013;3(1):1-2
pubmed: 23382779
Ann Oncol. 2013 Apr;24(4):857-77
pubmed: 23425945
Ann Oncol. 2013 Oct;24 Suppl 6:vi144-8
pubmed: 24078657
Clin Cancer Res. 2014 Jun 1;20(11):2984-93
pubmed: 24696320
Oncotarget. 2015 Mar 10;6(7):5022-40
pubmed: 25669980
EMBO Mol Med. 2015 Mar 03;7(4):477-87
pubmed: 25736399
Theranostics. 2015 Mar 01;5(6):618-30
pubmed: 25825601
Blood. 2015 Jul 9;126(2):222-32
pubmed: 26031918
J Nucl Med. 2016 Feb;57(2):248-51
pubmed: 26564323
J Cancer Res Clin Oncol. 2016 Nov;142(11):2239-47
pubmed: 27544389
J Neuroimmunol. 1997 Nov;79(2):148-54
pubmed: 9394787
Nature. 1998 Jun 11;393(6685):595-9
pubmed: 9634238